Estimated GFR decline as a surrogate end point for kidney failure: A post hoc analysis from the reduction of end points in non-insulin-dependent diabetes with the Angiotensin II Antagonist Losartan (RENAAL) study and Irbesartan Diabetic Nephropathy Trial (IDNT)

American Journal of Kidney Diseases

Volumn 63, Issue 2, 2014, Pages 244-250

  Lambers Heerspink, Hiddo J ^a   Weldegiorgis, Misghina ^a   Inker, Lesley A ^b   Gansevoort, Ron ^a   Parving, Hans Henrik ^c   Dwyer, Jamie P ^d   Mondal, Hasi ^b   Coresh, Josef ^e   Greene, Tom ^f   Levey, Andrew S ^b   De Zeeuw, Dick ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b TUFTS MEDICAL CENTER   (United States)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

^d VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^f UNIVERSITY OF UTAH   (United States)

Author keywords

angiotensin receptor blocker; clinical trial; disease progression; end stage renal disease; kidney disease trajectory; kidney end point; nephropathy; renal function; Type 2 diabetes

Indexed keywords

AMLODIPINE; CREATININE; HEMOGLOBIN; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; IRBESARTAN; LOSARTAN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; BIOLOGICAL MARKER; BIPHENYL DERIVATIVE; TETRAZOLE DERIVATIVE;

ADULT; ALBUMINURIA; ARTICLE; BODY MASS; CREATININE BLOOD LEVEL; DIABETIC NEPHROPATHY; DIASTOLIC BLOOD PRESSURE; DISEASE COURSE; DRUG DOSE INCREASE; DRUG DOSE TITRATION; END STAGE RENAL DISEASE; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; POST HOC ANALYSIS; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENAL REPLACEMENT THERAPY; SYSTOLIC BLOOD PRESSURE; THERAPY EFFECT; AGED; BLOOD; CONTROLLED STUDY; DIABETES MELLITUS, TYPE 2; DOUBLE BLIND PROCEDURE; KIDNEY FAILURE, CHRONIC; PATHOPHYSIOLOGY; PHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL;

AGED; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; BIOLOGICAL MARKERS; BIPHENYL COMPOUNDS; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY FAILURE, CHRONIC; LOSARTAN; MALE; MIDDLE AGED; TETRAZOLES;

EID: 84892925764     PISSN: 02726386     EISSN: 15236838     Source Type: Journal    
DOI: 10.1053/j.ajkd.2013.09.016     Document Type: Article

References (14)

1. B.M. Brenner, M.E. Cooper, and D. de Zeeuw et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy N Engl J Med 345 12 2001 861 869
2. E.J. Lewis, L.G. Hunsicker, and W.R. Clarke et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes N Engl J Med 345 12 2001 851 860
3. A. Patel, S. MacMahon, and J. Chalmers et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial Lancet 370 9590 2007 829 840
4. A.J. Palmer, L. Annemans, and S. Roze et al. Cost-effectiveness of early irbesartan treatment versus control (standard antihypertensive medications excluding ACE inhibitors, other angiotensin-2 receptor antagonists, and dihydropyridine calcium channel blockers) or late irbesartan treatment in patients with type 2 diabetes, hypertension, and renal disease Diabetes Care 27 8 2004 1897 1903
5. A.J. Apperloo, D. de Zeeuw, and P.E. de Jong A short-term antihypertensive treatment-induced fall in glomerular filtration rate predicts long-term stability of renal function Kidney Int 51 3 1997 793 797
6. S. Hirsch, J. Hirsch, U. Bhatt, and B.H. Rovin Tolerating increases in the serum creatinine following aggressive treatment of chronic kidney disease, hypertension and proteinuria: pre-renal success Am J Nephrol 36 5 2012 430 437
7. F.A. Holtkamp, D. de Zeeuw, and M.C. Thomas et al. An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal function Kidney Int 80 3 2011 282 287
8. B.M. Brenner, M.E. Cooper, and D. de Zeeuw et al. The losartan renal protection study -rationale, study design and baseline characteristics of RENAAL (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan) J Renin Angiotensin Aldosterone Syst 1 4 2000 328 335
9. R.A. Rodby, R.D. Rohde, and W.R. Clarke et al. The Irbesartan Type II Diabetic Nephropathy Trial: study design and baseline patient characteristics. For the Collaborative Study Group Nephrol Dial Transplant 15 4 2000 487 497
10. A.S. Levey, L.A. Stevens, and C.H. Schmid et al. A new equation to estimate glomerular filtration rate Ann Intern Med 150 9 2009 604 612
11. M. Evans, S.C. Bain, S. Hogan, and R.W. Bilous Irbesartan delays progression of nephropathy as measured by estimated glomerular filtration rate: post hoc analysis of the Irbesartan Diabetic Nephropathy Trial Nephrol Dial Transplant 27 6 2011 2255 2263
12. S. Anderson, T.W. Meyer, H.G. Rennke, and B.M. Brenner Control of glomerular hypertension limits glomerular injury in rats with reduced renal mass J Clin Invest 76 2 1985 612 619
13. MDRD Study Group Effects of dietary protein restriction on the progression of moderate renal disease in the Modification of Diet in Renal Disease Study J Am Soc Nephrol 7 12 1996 2616 2626
14. T. Greene A model for a proportional treatment effect on disease progression Biometrics 57 2 2001 354 360